STRATA Skin Sciences (SSKN) 10-Q14 Aug 142014 Q2 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2014	Jul. 31, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'MELA	'
Entity Registrant Name	'MELA SCIENCES, INC. /NY	'
Entity Central Index Key	'0001051514	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	5,214,852

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$4,202,279	$3,782,881	[1]
Accounts receivable (net of allowance of $43,080 and $46,130 as of June 30, 2014 and December 31, 2013, respectively)	49,472	57,151	[1]
Inventory (net of reserve of $863,559 as of June 30, 2014 and $325,000 as of December 31, 2013)	3,946,852	5,631,205	[1]
Prepaid expenses and other current assets	332,327	879,698	[1]
Total Current Assets	8,530,930	10,350,935	[1]
Property and equipment, net	3,872,574	3,690,784	[1]
Patents and trademarks, net	39,257	41,795	[1]
Other assets	48,000	48,000	[1]
Total Assets	12,490,761	14,131,514	[1]
Current Liabilities:	'	'
Accounts payable (includes related parties of $35,554 and $32,902 as of June 30, 2014 and December 31, 2013, respectively)	1,116,913	1,478,995	[1]
Accrued expenses (includes related parties of $0 and $48,000 as of June 30, 2014 and December 31, 2013, respectively)	302,834	844,131	[1]
Deferred placement revenue	151,508	243,605	[1]
Warrant liability	3,559,227	3,017,142	[1]
Other current liabilities	103,348	67,934	[1]
Total Current Liabilities	5,233,830	5,651,807	[1]
Long-Term Liabilities:	'	'
Deferred placement revenue	14,787	63,754	[1]
Deferred rent	100,102	120,120	[1]
Total Long-Term Liabilities	114,889	183,874	[1]
Total Liabilities	5,348,719	5,835,681	[1]
COMMITMENTS AND CONTINGENCIES	'	'	[1]
Stockholders' Equity:	'	'
Preferred stock - $0.10 par value; authorized 10,000,000 shares: issued and outstanding: 12,300 at June 30, 2014 and 0 at December 31, 2013	1,230	'
Common stock - $0.001 par value; authorized 50,000,000 shares: issued and outstanding 5,213,969 shares at June 30, 2014 and 4,750,160 at December 31, 2013	5,214	4,750	[1]
Additional paid-in capital	182,637,024	176,438,961	[1]
Accumulated deficit	-175,501,426	-168,147,878	[1]
Total Stockholders' Equity	7,142,042	8,295,833	[1]
Total Liabilities and Stockholders' Equity	$12,490,761	$14,131,514	[1]

[1]	Derived from the audited balance sheet as of December 31, 2013

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Allowance for accounts receivable, current	$43,080	$46,130	[1]
Inventory reserves	863,559	325,000	[1]
Accounts payable, related parties	35,554	32,902	[1]
Accrued expenses, related parties	$0	$48,000	[1]
Preferred stock, par value	$0.10	$0.10	[1]
Preferred stock, shares authorized	10,000,000	10,000,000	[1]
Preferred stock, shares issued	12,300	0	[1]
Preferred stock, shares outstanding	12,300	0	[1]
Common stock, par value	$0.00	$0.00	[1]
Common stock, shares authorized	50,000,000	50,000,000	[1]
Common stock, shares issued	5,213,969	4,750,160	[1]
Common stock, shares outstanding	5,213,969	4,750,160	[1]

[1]	Derived from the audited balance sheet as of December 31, 2013

Condensed_Statements_of_Operat

Condensed Statements of Operations (USD $)	3 Months Ended		6 Months Ended
Condensed Statements of Operations (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Net revenues	$225,155	$144,399	$322,793	$288,499
Cost of revenue	1,277,061	1,381,447	2,195,584	2,461,710
Gross Profit	-1,051,906	-1,237,048	-1,872,791	-2,173,211
Operating expenses:	'	'	'	'
Research and development	370,648	1,122,962	1,078,472	2,384,963
Selling, general and administrative	2,835,548	4,672,540	6,039,081	8,959,768
Total operating expenses	3,206,196	5,795,502	7,117,553	11,344,731
Operating Loss	-4,258,102	-7,032,550	-8,990,344	-13,517,942
Other income (expenses):	'	'	'	'
Interest income	688	2,710	1,306	4,815
Interest expense	-1,158	-291,622	-2,357	-340,385
Change in fair value of warrant liability	4,905,638	-105,292	5,042,780	-89,859
Registration rights liquidated damages	-29,758	'	-3,419,698	'
Other income, net	9,740	5,000	14,765	10,000
Total Other Income/(Loss)	4,885,150	-389,204	1,636,796	-415,429
Net Income/(Loss)	$627,048	($7,421,754)	($7,353,548)	($13,933,371)
Basic net income/(loss) per common share	$0.12	($1.72)	($1.46)	($3.38)
Diluted net income/(loss) per common share	$0.12	($1.72)	($1.46)	($3.38)
Basic weighted average number of common shares outstanding	5,212,765	4,308,660	5,053,587	4,117,091
Diluted weighted average number of common shares outstanding	5,212,765	4,308,660	5,053,587	4,117,091

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	6 Months Ended
Condensed Statements of Cash Flows (USD $)	Jun. 30, 2014		Jun. 30, 2013
Cash flows from operating activities:	'		'
Net loss	($7,353,548)		($13,933,371)
Adjustments to reconcile net loss to net cash used in operating activities:	'		'
Depreciation and amortization	881,535		1,107,009
Bad debt expense	700		40,290
Inventory reserve	538,559		325,000
Non-cash interest expense	'		98,706
Change in fair value of warrant liability	-5,042,780		89,859
Write-off of unamortized financing costs	'		41,166
Stock-based equity compensation	332,115		1,097,106
Gain on sale of fixed assets	-4,740		'
Changes in operating assets and liabilities:	'		'
Accounts receivable	6,979		-68,593
Inventory	21,509		74,100
MelafindÂ®systems sold	62,238		'
Prepaid expenses and other current assets	547,371		218,204
Other assets	'		-3,500
Accounts payable and accrued expenses	-903,379		224,958
Other current liabilities	35,414		12,981
Deferred revenue	-141,064		130,653
Deferred rent	-20,018		-11,826
Long-term interest payable	'		51,922
Net cash used in operating activities	-11,039,109		-10,505,336
Cash flows from investing activities:	'		'
Purchases of property and equipment	'		-3,766,264
Proceeds from the sale of fixed assets	6,000		'
Net cash provided by (used in) investing activities	6,000		-3,766,264
Cash flows from financing activities:	'		'
Net proceeds from private placements/public offerings	11,452,507		15,789,873
Net proceeds from long-term debt	'		6,000,000
Expenses related to borrowings and issuance of warrant	'		-245,358
Proceeds from exercise of stock options	'		18,059
Net cash provided by financing activities	11,452,507		21,562,574
Net increase in cash and cash equivalents	419,398		7,290,974
Cash and cash equivalents at beginning of period	3,782,881	[1]	7,861,524
Cash and cash equivalents at end of period	4,202,279		15,152,498
Non-cash investing activity:	'		'
Reclassification of warrant liability to stockholders' equity	'		$652,442

[1]	Derived from the audited balance sheet as of December 31, 2013

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	6 Months Ended
Organization and Basis of Presentation	Jun. 30, 2014
Accounting Policies [Abstract]	'
Organization and Basis of Presentation	'
	1. ORGANIZATION AND BASIS OF PRESENTATION
	The accompanying unaudited condensed financial statements of MELA Sciences, Inc., a Delaware corporation (“MELA” or the “Company”), have been prepared in accordance with the instructions to Form 10-Q and therefore do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (“GAAP”); however, such information reflects all adjustments (consisting solely of normal recurring adjustments) that are, in the opinion of management, necessary for a fair statement of the results for the interim periods.
	The condensed financial statements should be read in conjunction with the consolidated financial statements and notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. In addition, some of the Company’s statements in this Quarterly Report on Form 10-Q may involve risks and uncertainties that could significantly impact expected future results. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of results to be expected for the full year.
	The Company is a medical technology company dedicated to designing and developing innovative software-driven technology for the clinical early detection and prevention of skin cancer. The Company is primarily focused on the commercialization of its flagship product, the MelaFind® system, and the further design and development of MelaFind® and its technology. The MelaFind® system is an optical diagnostic device that assists dermatologists in the diagnosis of melanoma. It features a hand-held component that uses light of differing wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms that have been ‘trained’ and blind tested on the Company’s proprietary database of melanomas and benign lesions. The MelaFind® system then provides images and objective data on the relative disorganization of a lesion’s structure that provides substantial additional perspective to assist physicians in the clinical management decision for atypical pigmented skin lesions, including information useful in the decision whether to biopsy the lesion.
	In November 2011, the Company received written approval from the U.S. Food and Drug Administration (“FDA”) for the MelaFind® Pre-Market Approval (“PMA”) application and in September 2011 received Conformite Europeenne (“CE”) Mark approval. In March 2012, the Company installed the first commercial MelaFind® systems, and proceeded with the commercial launch of MelaFind®. The Company is currently conducting a Post-Approval Study (“PAS”) evaluating the sensitivity and false positive rate of physicians after using the MelaFind® system with their performance if MelaFind® was not available.
	The launch of MelaFind® in 2012 and the subsequent commercialization activities supporting the launch did not meet the Company’s initial goals and objectives. Revenues were lower than forecasted and expenses continued to increase throughout 2012 and into 2013. In the third quarter of 2013, a significant cost reduction program was put into place. In November 2013, the Company adopted a refocused “Go-to-Market” strategy concentrating on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma. The Company also changed its business model for the MelaFind® system from a rental-based to a sales-based model. The Company has reduced its costs, added more experience to its management team, and reorganized its sales and marketing activities.
	On August 22, 2013, the Company received a notice from The NASDAQ Stock Market (“NASDAQ”) that, for the previous 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. In July 2014, the Company effected a one-for-ten reverse split of its common stock in order to regain compliance with the minimum bid price requirement prior to the expiration of the last applicable grace period. On July 24, 2014, the Company was notified by NASDAQ that it is now in compliance with the minimum bid price requirement.
	In July 2014, MELA announced that it took the first step in the process of obtaining insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (“MSDSLA”) procedure that is performed by dermatologists utilizing the MelaFind® system as an aid in the detection of melanoma. The Company submitted an application for a Current Procedural Terminology (“CPT®”) code, which is necessary for Medicare Part B reimbursement by the Centers for Medicare and Medicaid Services (“CMS”). Currently, there is no CPT code available for the MelaFind® process. The Company plans to commence efforts to obtain reimbursement from private insurers during the CMS’ coverage determination process, which is expected to take at least 18 months.
	MELA has experienced recurring losses and negative cash flow from operations and management expects these conditions to continue for the foreseeable future. As a result of these factors, the Company has been and continues to be dependent on raising capital from the sale of securities in order to operate and to meet its obligations in the ordinary course of business. In February 2014, the Company raised net proceeds of approximately $11.5 million from the sale of Series A Preferred Stock, common stock and warrants to strengthen the Company’s financial position (see Note 11). In July 2014, the Company raised an additional $14 million in net proceeds from the sale of senior secured convertible debt (see Note13).

	The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Interim results may not be indicative of the results that may be expected for the year. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has devoted substantially all of its cash resources to the development and marketing of the MelaFind® system and general and administrative expenses, and to date it has not generated any significant revenues from the sale of products. As a result, MELA has an accumulated deficit of $175.5 million as of June 30, 2014. The Company’s recurring losses from operations and the accumulated deficit raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Even if the Company succeeds in commercializing the MelaFind® system it may never become profitable. The Company expects to continue to incur significant expenses over the next several years.

Use_of_Estimates

Use of Estimates	6 Months Ended
Use of Estimates	Jun. 30, 2014
Text Block [Abstract]	'
Use of Estimates	'
	2. USE OF ESTIMATES
	The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements, the use of estimates to determine the elements of our revenue and deferred revenue, accrued expenses, and the warrant liability. Actual results could differ from these estimates. Estimates of future operating results are based upon numerous factors including past experience, known information and subjective estimates and assumptions. Actual future operating results could be materially different from management’s estimates and unforeseen events could adversely affect management’s estimates.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	6 Months Ended
Recent Accounting Pronouncements	Jun. 30, 2014
Accounting Changes And Error Corrections [Abstract]	'
Recent Accounting Pronouncements	'
	3. RECENT ACCOUNTING PRONOUNCEMENTS
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09,”Revenue from Contracts with Customers (Topic 606),” (“ASU 2014-09”). ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016 and interim periods within those periods. Early adoption is not permitted. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company is currently assessing the impact that adopting this new accounting guidance will have on its consolidated financial statements and footnote disclosures.

Inventory

Inventory	6 Months Ended
Inventory	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory	'
	4. INVENTORY
	Inventories currently consist of MelaFind® systems and other finished products and accessories that are stated at the lower of cost or market value. Inventory accessories are purchased items to be sold for use in the operation of the MelaFind® systems. The Company maintains a reserve for specific inventory items that are no longer being used in the devices.
	In December 2013, the Company changed its business model for the MelaFind® system from a rental-based model to a sales-based model. In accordance with this new sales model, the Company reclassified approximately $5.4 million of MelaFind® systems from property and equipment into inventory at December 31, 2013. The systems reclassified into inventory represent systems available for sale.
	During the second quarter of 2014, the Company ceased repairs of certain of its MelaFind system units that it determined were unlikely to be sold during the next several periods. The Company estimated the cost to restore its system units to sellable condition and created a repair reserve amounting to $0.5 million at June 30, 2014.

	Inventory consists of the following:


		June 30,			December 31,
		2014			2013
	MelaFind® Systems	$	4,277,581		$	5,401,866
	Mela record cards		327,748			327,900
	Accessories		205,082			226,439

			4,810,411			5,956,205
	Reserve for obsolete inventory		(325,000	)		(325,000	)
	Reserve for inventory repairs		(538,559	)		—

			3,946,852		$	5,631,205

Property_and_Equipment_Net

Property and Equipment, Net	6 Months Ended
Property and Equipment, Net	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Property and Equipment, Net	'
	5. PROPERTY AND EQUIPMENT, NET
	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered to be impaired when the sum of the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposition exceeds its carrying amount. The amount of impairment loss, if any, is measured as the difference between the net book value of the asset and its estimated fair value.
	In December 2013, the Company changed its business model for the MelaFind® system from a rental-based to a sales-based model. In accordance with this new sales model, the Company reclassified approximately $5.4 million of MelaFind® systems from property and equipment into inventory at December 31, 2013. The systems reclassified into inventory represent systems available for sale. Systems that have been leased under the rental-based model remain in property and equipment.
	During the quarter, the Company reclassified $725,598 of accumulated depreciation related to MelaFind system components that were previously leased and are now available for sale that were included in inventory at December 31, 2013.
	Property and equipment, at cost, consists of the following:


		June 30,			December 31,			Estimated
		2014			2013			Useful Life
	Leasehold improvements	$	905,888		$	905,888			Lease Term
	Laboratory and research equipment		1,083,661			1,083,661			3-5 years
	Office furniture and equipment		2,005,344			2,022,833			3-5 years
	MelaFind® Systems		5,185,073			5,081,816

			9,179,966			9,094,198
	Accumulated depreciation and amortization		(5,307,392	)		(5,403,414	)

		$	3,872,574		$	3,690,784

	Depreciation expense for the three and six months ended June 30, 2014 was $183,466 and $878,997, respectively, and June 30, 2013 was $609,007 and $1,104,034, respectively.

Net_IncomeLoss_Per_Common_Shar

Net Income/(Loss) Per Common Share	6 Months Ended
Net Income/(Loss) Per Common Share	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Net Income/(Loss) Per Common Share	'
	6. NET INCOME/(LOSS) PER COMMON SHARE
	Basic net income/(loss) per common share excludes dilution for potentially dilutive securities and is computed by dividing net income/(loss) attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net income/(loss) per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net income/(loss) per common share is equal to the basic net income/(loss) per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents outstanding as of June 30, 2014 and June 30, 2013 consist of common stock equivalents of convertible preferred stock, stock options, common stock purchase warrants and restricted stock, which are summarized as follows:


		June 30,
		2014		2013
	Common stock equivalents of convertible preferred stock		1,464,287		—
	Common stock options		340,028		293,714
	Common stock purchase warrants		2,084,767		89,321
	Restricted stock awards		2,890		—

	Total		3,891,972		383,035

Comprehensive_Loss

Comprehensive Loss	6 Months Ended
Comprehensive Loss	Jun. 30, 2014
Equity [Abstract]	'
Comprehensive Loss	'
	7. COMPREHENSIVE LOSS
	For all periods presented, the Company had no comprehensive income items and accordingly there is no difference between the reported net loss and per share amounts per the Statement of Operations and comprehensive net loss and related per share amounts.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
Stock-Based Compensation	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	8. STOCK-BASED COMPENSATION
	Stock awards under the Company’s stock option plans have been granted with exercise prices that are no less than the market value of the stock on the date of the grant. Options granted under the 2013 and 2005 Plans are generally time-based or performance-based options and vesting varies accordingly. Options under the plans expire up to a maximum of ten years from the date of grant.
	The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:


		June 30,
		2014		2013
	Expected life		6.5 years		5.5-6.5 years
	Expected volatility		75.51-73.87%		71.71%-76.83%
	Risk-free interest rate		2.14-2.45%		.71-1.95%
	Dividend yield		—		—
	Stock-based compensation expense for the three and six months ended June 30, 2014 was $167,947 and $312,663, respectively, and for the three and six months ended June 30, 2013 was $749,225 and $1,017,606, respectively.

Debt

Debt	6 Months Ended
Debt	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	9. DEBT
	On March 15, 2013, the Company executed loan documents with Hercules Technology Growth Capital Inc. (“Hercules”), a venture capital lender, whereby the Company borrowed $6 million (the “Loan”). The Loan accrued interest at a rate of 10.45%. The term of the Loan was 42 months with interest payments only during the first 12 months. On September 10, 2013, the Company elected to prepay the Loan and paid Hercules approximately $6.4 million, including the end of term fee of $425,000, to settle all obligations to Hercules. Hercules agreed to waive the prepayment penalty of $180,000.
	Upon executing the loan documents on March 15, 2013 the Company became obligated to issue to the Lender a warrant to purchase shares of the Company’s common stock upon approval by the Company’s stockholders of a proposal to increase the Company’s number of authorized shares of common stock at its 2013 Annual Meeting of Stockholders. The number of shares that could be acquired upon exercise of the warrant and the exercise price per share were not fixed on March 15, 2013, but would be determined when the warrant was issued based on a defined formula using trading prices of the Company’s common stock during certain periods prior to the issuance of the warrant. The Company’s stockholders approved the increase in the number of authorized shares of common stock on April 25, 2013 and on April 26, 2013 the warrant was issued to the Lender. The terms of the warrant were fixed on the date of issuance whereby the Lender received a warrant to purchase 69,321 shares of common stock at an exercise price of approximately $11.20 per share. The warrant expires on April 26, 2018.
	For financial reporting purposes, the $6 million funded by the Lender on March 15, 2013 was allocated first to the fair value of the obligation to issue the warrant, which totaled approximately $563,000, and the balance was reduced further by the Lender’s costs and fees, resulting in an initial carrying value of the loan of approximately $5.3 million. The Company used a Level 3 fair value measurement to determine fair value of the warrant obligation, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. During the period from the loan inception date until the warrant obligation was fulfilled and the warrant was issued, the warrant obligation was reflected as a long-term liability at fair value. Changes in the fair value (“mark-to-market adjustments”) of the warrant obligation of approximately $105,292 and $89,859 are included in operating results for the three and six months ended June 30, 2013. The fair value of the warrant obligation was determined using the Monte Carlo pricing model that used various assumptions that included: stock prices ranging from $11.60 to $11.80 per share, volatility of 77%, time to maturity of 5 years, exercise prices ranging from $11.50 to $11.60 and a risk free interest rate of return of .84%. Under the Monte Carlo model, a 10% change in the underlying unobservable inputs would not have a significant impact on the fair value.
	The value of the warrant obligation combined with the costs resulted in an initial loan discount of approximately $727,000. The terms of the Loan required us to pay the Lender a fee of $425,000 at the maturity of the Loan. The loan discount and the fee were being amortized as additional interest expense over the life of the loan using the interest method. As discussed above, prior to the terms of the warrant being fixed on April 26, 2013, the warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative reflected as a long-term liability until the warrant was issued on April 26, 2013. The terms of the warrant upon issuance no longer required derivative accounting under ASC 815 and therefore the fair value of the warrant was classified within stockholders equity.
	As the result of the Company electing to prepay the loan on September 10, 2013, the unamortized loan discount, fee and deferred financing costs that were expensed at that date were approximately $1.0 million.

Reverse_Split_of_Common_Stock

Reverse Split of Common Stock	6 Months Ended
Reverse Split of Common Stock	Jun. 30, 2014
Text Block [Abstract]	'
Reverse Split of Common Stock	'
	10. REVERSE SPLIT OF COMMON STOCK
	On July 9, 2014, the Company effected a previously authorized 1-for-10 reverse stock split of its common stock. The reverse split took effect at the start of trading on July 10, 2014 on a 1-for-10 split basis. All prior periods have been retroactively adjusted to reflect the reverse stock split.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	11. STOCKHOLDERS’ EQUITY
	Preferred Stock
	The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors.
	On February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, the Company sold to the Purchasers (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, par value $0.10 and a stated value of $1,000 per share, convertible into 1,464,287 shares of common stock at an initial conversion price of $8.40, and (ii) warrants to purchase up to 1,329,731 shares of common stock for net proceeds of $11.4 million. The warrants have an exercise price of $7.40 per share, are immediately exercisable and have a term of five years. These warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative liability and recorded at fair value on the inception date of February 5, 2014. They will be recorded at their respective fair value at each subsequent balance sheet date. The fair value of these warrants on June 30, 2014 was approximately $2,393,513. The change in fair value of these warrants for the three and six months ended June 30, 2014 was a benefit of $3,191,352.
	In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of approximately $3.4 million. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000.

	Common Stock
	The Company is authorized to issue 50,000,000 shares of common stock with a par value of $0.001 per share.
	On October 29, 2013, the Company entered into a securities purchase agreement with certain accredited investors in connection with a $6.0 million registered offering of 422,819 shares of the Company’s common stock, fully paid prefunded warrants (“Series B Warrants”) to purchase up to 434,325 shares of its common stock and additional warrants (“Series A Warrants”) to purchase up to 685,715 shares of its common stock. The Series A Warrants are exercisable beginning on May 1, 2014 at a price of $8.50 per share and expire on May 1, 2019. The Series B Warrants are exercisable immediately for no additional consideration. The offering closed on October 31, 2013.
	The holders exercised 200,000 and 234,325 on March 5, 2014 and March 7, 2014, respectively, of the Series B Warrants. There were no warrant exercises in the first six months of 2013.
	The Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value at the inception date of October 31, 2013, and will be recorded at their respective fair values at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as a non-operating, non-cash charge in the Statements of Operations. The change in fair value of these warrants for the three and six months ended June 30, 2014, was a benefit of $1,714,826 and $1,851,428, respectively.
	On February 12, 2013 the Company entered into an underwriting agreement with Cowen and Company, LLC, relating to the public offering of 610,000 shares of the Company’s common stock, at a price to the public of $13.00 per share less underwriting discounts and commissions. The gross proceeds to the Company from the sale of the Common Stock totaled $7.9 million. After deducting the underwriters’ discounts and commissions and other estimated offering expenses payable by the Company, net proceeds were approximately $7.3 million. The offering closed on February 15, 2013.
	In June 2012, the Company entered into a sales agreement with Cowen and Company, LLC, to sell shares of the Company’s common stock through an “at-the-market” equity offering program (the “ATM Program”), which was terminated on February 15, 2013. During the three months ended March 31, 2013, and in connection with its termination, the Company sold approximately 470,000 shares under the ATM Program for gross and net proceeds of approximately $8.8 million and $8.5 million, respectively. During the term of the ATM Program, the Company sold a total of approximately 660,000 shares for aggregate gross and net proceeds of approximately $14.4 million and $13.8 million, respectively.
	On August 22, 2013, the Company received a notice from NASDAQ that, for the previous 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. In July 2014, the Company effected a one-for-ten reverse split of its common stock in order to regain compliance with the minimum bid price requirement prior to the expiration of the last applicable grace period. On July 24, 2014, the Company was notified by NASDAQ that it is now in compliance with the minimum bid price requirement.
	Outstanding common stock warrants consist of the following:


			Total
	Issue Date	Expiration Date	Warrants		Ex. Price
	4/26/13	4/26/18		69,321	$	11.18
	10/31/13	10/31/18		685,715	$	8.5
	2/5/14	2/5/19		1,329,731	$	7.4

				2,084,767

	During the three months ended June 30, 2014, the number of outstanding shares of the Company’s common stock increased from 5,210,747 to 5,213,969.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	6 Months Ended
Fair Value of Financial Instruments	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	12. FAIR VALUE OF FINANCIAL INSTRUMENTS
	Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows:

		•		Level 1: Observable inputs such as quoted prices in active markets;

		•		Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

		•		Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The Company’s financial instruments are cash and cash equivalents, accounts payable, and derivative warrant liabilities. The recorded values of cash equivalents and accounts payable approximate their fair values based on their short-term nature. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of our warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures.
	The warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon change in control of the Company and therefore are classified as a derivative. These warrants have been recorded at their fair value using the Black-Scholes pricing model and will be recorded at their respective fair value at each subsequent balance sheet date.
	A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of June 30, 2014 and December 31, 2013 is as follows:


			June 30, 2014			December 31, 2013
	Stock Price		$	3.2		$	6.4
	Risk-free Rate (5-year U.S. Treasury Yield)			1.62%			1.75%
	Volatility (Annual)			93.46%			93.43%
	Time to Maturity (Years)			4.60-4.83			5.33
	Derivative warrant liabilities consist of the following:


			Fair Value
			Measurements Using
			Significant
			Unobservable Inputs
			(Level 3)
			Warrant Derivative
			Liabilities
	Beginning balance at January 1, 2014		$	3,017,142
	Issuance of warrants with derivative liabilities			5,584,865
	Changes in estimated fair value			(5,042,780	)

	Ending balance at June 30, 2014		$	3,559,227

Subsequent_Events

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	13. SUBSEQUENT EVENTS
	On August 6, 2014, the Company and Askion GmbH entered into an “Amended and Restated Askion Production Agreement.” This agreement is a mutual settlement and release agreement of two prior unfulfilled purchase orders. The settlement amount of $1,141,644 will be used for future inventory purchases and will be paid to Askion in 9 installments.
	On July 21, 2014, the Company entered into a definitive Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with institutional investors providing for the issuance of (i) 12,300 shares of Series B convertible preferred stock (the “Preferred Stock”) at a price of $1,000 per share, (ii) Senior Secured Convertible Debentures in the aggregate principal amount of $15,000,000, due, subject to the terms therein, in July 2019 (the “Debentures”), and (iii) warrants (the “Warrants”) to purchase up to an aggregate of approximately 11.0 million shares of common stock, $0.001 par value per share (the “Common Stock”), at an exercise price of $2.45 per share (the “Offering”). The Offering closed on July 24, 2014.
	The proceeds of the Offering will be used to redeem all of the Company’s outstanding shares of Series A convertible preferred stock and for general working capital purposes.
	The Preferred Stock is convertible into an aggregate of approximately 4.8 million shares of Common Stock and the Debentures are convertible into an aggregate of approximately 5.8 million shares of Common Stock. The Debentures and the shares of Preferred Stock and Warrants described above have not been registered under the Securities Act of 1933, as amended (the “Securities Act”).

	Subject to certain ownership limitations, the Preferred Stock and Debentures are convertible at any time into shares of Common Stock at an initial conversion price of $2.565 per share (which represents a price above the closing bid price of the Common Stock on July 18, 2014, the trading day immediately prior to the entry into the Purchase Agreement). The Preferred Stock is only entitled to dividends in the event that dividends are paid on the Common Stock, and the Preferred Stock will not have any preferences over the Common Stock, including liquidation rights. The Warrants are also subject to certain ownership limitations and are immediately exercisable. 4.8 million of the Warrants will expire eighteen months from the date of issuance, and 6.2 million of the Warrants will expire five years from the date of issuance.
	The Company has also entered into a Registration Rights Agreement with the investors pursuant to which the Company is obligated to file a registration statement within 30 days to register for resale the shares of Common Stock issuable upon conversion of the Preferred Stock and Debentures and upon exercise of the Warrants. If the Company is unable to meet certain filing and effectiveness requirements it could be required to pay up to a maximum penalty of $3.3 million plus interest in liquidating damages.
	The Debentures will bear interest at an annual rate of 4%, payable quarterly or upon conversion into shares of Common Stock registered under the Securities Act. The Company’s obligations under the Debentures are secured by a first priority lien on all of the Company’s intellectual property pursuant to the terms of a security agreement (“Security Agreement”) dated July 21, 2014 among the Company and the investors.
	Pursuant to the Purchase Agreement, until eighteen months following the effective date of the registration statement covering the resale of the shares underlying the Preferred Stock, Debentures and Warrants, or the date on which such shares may be resold pursuant to Rule 144 under the Securities Act, the investors have the right, but not the obligation, to participate in any financing that the Company undertakes, up to 50% of the aggregate amount of securities being offered.

Recent_Accounting_Pronouncemen1

Recent Accounting Pronouncements (Policies)	6 Months Ended
Recent Accounting Pronouncements (Policies)	Jun. 30, 2014
Accounting Changes And Error Corrections [Abstract]	'
Recent Accounting Pronouncements	'
Recent Accounting Pronouncements	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09,”Revenue from Contracts with Customers (Topic 606),” (“ASU 2014-09”). ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016 and interim periods within those periods. Early adoption is not permitted. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company is currently assessing the impact that adopting this new accounting guidance will have on its consolidated financial statements and footnote disclosures.

Inventory_Tables

Inventory (Tables)	6 Months Ended
Inventory (Tables)	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventory consists of the following:


		June 30,			December 31,
		2014			2013
	MelaFind® Systems	$	4,277,581		$	5,401,866
	Mela record cards		327,748			327,900
	Accessories		205,082			226,439

			4,810,411			5,956,205
	Reserve for obsolete inventory		(325,000	)		(325,000	)
	Reserve for inventory repairs		(538,559	)		—

			3,946,852		$	5,631,205

Property_and_Equipment_Net_Tab

Property and Equipment, Net (Tables)	6 Months Ended
Property and Equipment, Net (Tables)	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Summary of Property and Equipment	'
	Property and equipment, at cost, consists of the following:


		June 30,			December 31,			Estimated
		2014			2013			Useful Life
	Leasehold improvements	$	905,888		$	905,888			Lease Term
	Laboratory and research equipment		1,083,661			1,083,661			3-5 years
	Office furniture and equipment		2,005,344			2,022,833			3-5 years
	MelaFind® Systems		5,185,073			5,081,816

			9,179,966			9,094,198
	Accumulated depreciation and amortization		(5,307,392	)		(5,403,414	)

		$	3,872,574		$	3,690,784

Net_IncomeLoss_Per_Common_Shar1

Net Income/(Loss) Per Common Share (Tables)	6 Months Ended
Net Income/(Loss) Per Common Share (Tables)	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Common Stock Equivalents of Convertible Preferred Stock, Stock Options, Common Stock Purchase Warrants and Restricted Stock	'
	Potential common stock equivalents outstanding as of June 30, 2014 and June 30, 2013 consist of common stock equivalents of convertible preferred stock, stock options, common stock purchase warrants and restricted stock, which are summarized as follows:


		June 30,
		2014		2013
	Common stock equivalents of convertible preferred stock		1,464,287		—
	Common stock options		340,028		293,714
	Common stock purchase warrants		2,084,767		89,321
	Restricted stock awards		2,890		—

	Total		3,891,972		383,035

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
Stock-Based Compensation (Tables)	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Fair Value of Each Option Award Granted	'
	The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:


		June 30,
		2014		2013
	Expected life		6.5 years		5.5-6.5 years
	Expected volatility		75.51-73.87%		71.71%-76.83%
	Risk-free interest rate		2.14-2.45%		.71-1.95%
	Dividend yield		—		—

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
Stockholders' Equity (Tables)	Jun. 30, 2014
Equity [Abstract]	'
Schedule of Outstanding Common Stock Warrants	'
	Outstanding common stock warrants consist of the following:


			Total
	Issue Date	Expiration Date	Warrants		Ex. Price
	4/26/13	4/26/18		69,321	$	11.18
	10/31/13	10/31/18		685,715	$	8.5
	2/5/14	2/5/19		1,329,731	$	7.4

				2,084,767

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	6 Months Ended
Fair Value of Financial Instruments (Tables)	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value Hierarchy	'
	A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of June 30, 2014 and December 31, 2013 is as follows:


		June 30, 2014			December 31, 2013
	Stock Price	$	3.2		$	6.4
	Risk-free Rate (5-year U.S. Treasury Yield)		1.62%			1.75%
	Volatility (Annual)		93.46%			93.43%
	Time to Maturity (Years)		4.60-4.83			5.33
Schedule of Derivative Warrant Liabilities	'
	Derivative warrant liabilities consist of the following:


		Fair Value
		Measurements Using
		Significant
		Unobservable Inputs
		(Level 3)
		Warrant Derivative
		Liabilities
	Beginning balance at January 1, 2014	$	3,017,142
	Issuance of warrants with derivative liabilities		5,584,865
	Changes in estimated fair value		(5,042,780	)

	Ending balance at June 30, 2014	$	3,559,227

Organization_and_Basis_of_Pres1

Organization and Basis of Presentation - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended					0 Months Ended	1 Months Ended
	Aug. 22, 2013	Feb. 28, 2014	Jun. 30, 2014	Dec. 31, 2013		Aug. 22, 2013	Jul. 09, 2014	Jul. 31, 2014	Jul. 31, 2014
							Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
									Minimum [Member]
Condensed Financial Statements, Captions [Line Items]	'	'	'	'		'	'	'	'
Number of consecutive business days, non-compliance of minimum bid price	'30 days	'	'	'		'	'	'	'
Minimum bid price	'	'	'	'		$1	'	'	'
Reverse stock split, common stock	'	'	'	'		'	'One-for-ten reverse split of its common stock	'	'
Reverse stock split ratio, common stock	'	'	'	'		'	0.1	'	'
Expected period to obtain reimbursement	'	'	'	'		'	'	'	'18 months
Proceeds from sale of Series A Preferred Stock, common stock and warrants	'	$11,500,000	'	'		'	'	'	'
Proceeds from sale of senior secured convertible debt	'	'	'	'		'	'	14,000,000	'
Accumulated deficit	'	'	$175,501,426	$168,147,878	[1]	'	'	'	'

[1]	Derived from the audited balance sheet as of December 31, 2013

Inventory_Additional_Informati

Inventory - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Inventory [Line Items]	'	'
Inventory, Gross	$4,810,411	$5,956,205
Reserve for inventory	863,559	325,000	[1]
MelaFind Systems [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	4,277,581	5,401,866
Inventory Repairs [Member]	'	'
Inventory [Line Items]	'	'
Reserve for inventory	$538,559	'

[1]	Derived from the audited balance sheet as of December 31, 2013

Inventory_Schedule_of_Inventor

Inventory - Schedule of Inventory (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Inventory [Line Items]	'	'
Inventory, Gross	$4,810,411	$5,956,205
Reserve for inventory	-863,559	-325,000	[1]
Inventory, Net	3,946,852	5,631,205	[1]
MelaFind Systems [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	4,277,581	5,401,866
Mela Record Cards [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	327,748	327,900
Accessories [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	205,082	226,439
Obsolete Inventory [Member]	'	'
Inventory [Line Items]	'	'
Reserve for inventory	-325,000	-325,000
Inventory Repairs [Member]	'	'
Inventory [Line Items]	'	'
Reserve for inventory	($538,559)	'

[1]	Derived from the audited balance sheet as of December 31, 2013

Property_and_Equipment_Net_Add

Property and Equipment, Net - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Inventory, Gross	$4,810,411	'	$4,810,411	'	$5,956,205
Accumulated depreciation	5,307,392	'	5,307,392	'	5,403,414
Depreciation expense	183,466	609,007	878,997	1,104,034	'
MelaFind Systems [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Inventory, Gross	4,277,581	'	4,277,581	'	5,401,866
Accumulated depreciation	$725,598	'	$725,598	'	'

Property_and_Equipment_Net_Sum

Property and Equipment, Net - Summary of Property and Equipment (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Gross	$9,179,966	$9,094,198
Accumulated depreciation and amortization	-5,307,392	-5,403,414
Net	3,872,574	3,690,784	[1]
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross	905,888	905,888
Estimated Useful Life	'Lease Term	'
Laboratory and Research Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross	1,083,661	1,083,661
Estimated Useful Life	'3-5 years	'
Office Furniture and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross	2,005,344	2,022,833
Estimated Useful Life	'3-5 years	'
MelaFind Systems [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross	$5,185,073	$5,081,816

[1]	Derived from the audited balance sheet as of December 31, 2013

Net_IncomeLoss_Per_Common_Shar2

Net Income/(Loss) Per Common Share - Schedule of Common Stock Equivalents of Convertible Preferred Stock, Stock Options, Common Stock Purchase Warrants and Restricted Stock (Detail)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	3,891,972	383,035
Common Stock Equivalents of Convertible Preferred Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	1,464,287	'
Common Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	340,028	293,714
Restricted Stock Awards [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	2,890	'
Warrants Derivative Liabilities [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	2,084,767	89,321

Comprehensive_Loss_Additional_

Comprehensive Loss - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Net Income Loss [Abstract]	'	'
Comprehensive income (loss)	$0	$0

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	$167,947	$749,225	$332,115	$1,097,106
Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expiry period of option plan	'	'	'10 years	'

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Fair Value of Each Option Award Granted (Detail)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Expected life	'6 years 6 months	'6 years 6 months
Expected volatility - Minimum	75.51%	71.71%
Expected volatility - Maximum	73.87%	76.83%
Risk-free interest rate - Minimum	2.14%	0.71%
Risk-free interest rate - Maximum	2.45%	1.95%
Dividend yield	'	'

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

Sep. 10, 2013

Jun. 30, 2014

Dec. 31, 2013

Mar. 15, 2013

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Mar. 15, 2013

Jun. 30, 2014

Sep. 10, 2013

Mar. 15, 2013

Jun. 30, 2014

Warrant Obligation [Member]

Hercules Technology Growth Capital Inc. [Member]

Minimum [Member]

Maximum [Member]

Warrant Obligation [Member]

Debt Instrument [Line Items]

Loan payable

$6,000,000

Accrued interest rate

10.45%

Maturity period of loan

'42 months

Time period of interest payment

'First 12 months

Prepayment of loan

6,400,000

Term fee

425,000

Prepayment penalty

180,000

Warrants issued to purchase common stock

69,321

Warrants issued to purchase common stock, exercise price

11.2

Expiry date for warrant outstanding

26-Apr-18

Warrant issuance date

25-Apr-13

Fair value of warrant obligation

563,000

Initial carrying value of the loan

5,300,000

Changes in fair value of warrants

-1,714,826

-1,851,428

105,292

89,859

Stock prices

$11.60

$11.80

Volatility

93.46%

93.43%

77.00%

Maturity period

'5 years 3 months 29 days

'5 years

'4 years 7 months 6 days

'4 years 9 months 29 days

Exercise prices

$3.20

$6.40

$11.50

$11.60

Risk free interest rate of return

1.62%

1.75%

0.84%

Change in underlying unobservable inputs

10.00%

Initial loan discount amount

727,000

Loss on early extinguishment of debt

$1,000,000

Reverse_Split_of_Common_Stock_

Reverse Split of Common Stock - Additional Information (Detail) (Subsequent Event [Member])	0 Months Ended
	Jul. 09, 2014
Subsequent Event [Member]	'
Class of Stock [Line Items]	'
Reverse stock split, common stock	'One-for-ten reverse split of its common stock
Reverse stock split ratio, common stock	0.1
Reverse stock split, effective date	10-Jul-14

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

Apr. 03, 2014

Aug. 22, 2013

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Oct. 29, 2013

Aug. 22, 2013

Jul. 21, 2014

Jul. 09, 2014

Jul. 21, 2014

Feb. 05, 2014

Jun. 30, 2014

Feb. 12, 2013

Jun. 30, 2014

Mar. 31, 2013

Jun. 30, 2014

Mar. 07, 2014

Mar. 05, 2014

Oct. 29, 2013

Jun. 30, 2013

Oct. 29, 2013

Jun. 30, 2014

Oct. 29, 2013

Subsequent Event [Member]

Common Stock Equivalents of Convertible Preferred Stock [Member]

Securities Purchase Agreement [Member]

Shelf Registration Statement [Member]

ATM Program [Member]

Minimum [Member]

Maximum [Member]

Warrants Derivative Liabilities [Member]

Series B Prefunded Warrants [Member]

Series A Warrants [Member]

ATM Program [Member]

Securities Financing Transaction [Line Items]

Preferred stock, shares authorized

10,000,000

[1]

Preferred stock, par value

$0.10

[1]

Preferred stock, shares issued

12,300

[1]

12,300

Preferred stock, par value

$0.10

Preferred stock stated value, per share

$1,000

Preferred stock converted to common stock, shares

4,800,000

1,464,287

Preferred stock converted to common stock, conversion price

$8.40

Warrants issued to purchase common stock

11,000,000

1,329,731

Proceeds from issuance of warrants

$11,400,000

Warrants issued to purchase common stock, exercise price

2.45

7.4

8.5

Warrants issued, exercisable term

'5 years

Derivative fair value inception date

5-Feb-14

Fair Value of warrants

2,393,513

Change in fair value of warrants, benefit

1,714,826

1,851,428

3,191,352

Liquidated damages paid

29,758

3,419,698

Registration rights agreement description

'Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000

Additional liquidated damages payable

500,000

Common stock, shares authorized

50,000,000

[1]

Common stock, par value

$0.00

[1]

$0.00

Common stock issued

5,213,969

4,750,160

[1]

422,819

Warrants issued to purchase common stock

434,325

685,715

Proceeds from issuance of common stock and warrants

6,000,000

Warrants exercisable date

1-May-14

Warrants expiry date

1-May-19

Offering closed date

31-Oct-13

Warrants exercised

234,325

200,000

Public offering of common stock shares under underwriting agreement

610,000

Initial public offering price per share

$13

Gross proceeds from sale of common stock

7,900,000

Net proceeds from sale of common stock

7,300,000

Sales agreement termination date

15-Feb-13

Number of common stock issued through company ATM program

470,000

660,000

Gross proceeds from sale of common stock

8,800,000

14,400,000

Net proceeds from sale of common stock

$8,500,000

$13,800,000

Number of consecutive business days, non-compliance of minimum bid price

'30 days

Minimum bid price

Reverse stock split, description

'One-for-ten reverse split of its common stock

Reverse stock split ratio, common stock

0.1

Common stock outstanding

5,213,969

5,210,747

4,750,160

[1]

Derived from the audited balance sheet as of December 31, 2013

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Outstanding Common Stock Warrants (Detail)	6 Months Ended
	Jun. 30, 2014
Class of Warrant or Right [Line Items]	'
Total Warrants	2,084,767
Ex. Price $ 11.18 [Member]	'
Class of Warrant or Right [Line Items]	'
Issue Date	26-Apr-13
Expiration Date	26-Apr-18
Total Warrants	69,321
Ex. Price	11.18
Ex. Price $ 8.50 [Member]	'
Class of Warrant or Right [Line Items]	'
Issue Date	31-Oct-13
Expiration Date	31-Oct-18
Total Warrants	685,715
Ex. Price	8.5
Ex. Price $ 7.40 [Member]	'
Class of Warrant or Right [Line Items]	'
Issue Date	5-Feb-14
Expiration Date	5-Feb-19
Total Warrants	1,329,731
Ex. Price	7.4

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Stock Price	$3.20	$6.40
Risk-free Rate	1.62%	1.75%
Volatility (Annual)	93.46%	93.43%
Time to maturity (Years)	'	'5 years 3 months 29 days
Minimum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Time to maturity (Years)	'4 years 7 months 6 days	'
Maximum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Time to maturity (Years)	'4 years 9 months 29 days	'

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy (Parenthetical) (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'	'
U.S Treasury Yield, period	'5 years	'5 years

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Schedule of Derivative Warrant Liabilities (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013		Jun. 30, 2014
				Significant Unobservable Inputs (Level 3) [Member]
				Warrants Derivative Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'		'
Beginning balance at January 1, 2014	$3,559,227	$3,017,142	[1]	$3,017,142
Issuance of warrants with derivative liabilities	'	'		5,584,865
Changes in estimated fair value	'	'		-5,042,780
Ending balance at June 30, 2014	$3,559,227	$3,017,142	[1]	$3,559,227

[1]	Derived from the audited balance sheet as of December 31, 2013

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Aug. 06, 2014

Jul. 21, 2014

Aug. 06, 2014

Jul. 21, 2014

Subsequent Event [Member]

Purchases

Debentures [Member]

Warrants Expire in Eighteen Months [Member]

Warrants Expire in Five Years [Member]

Maximum [Member]

Series B Convertible Preferred Stock [Member]

Installment

Subsequent Event [Line Items]

Number of unfulfilled purchase orders

Settlement amount

$1,141,644

Number of installments

Preferred stock shares issued

12,300

Preferred stock stated value, per share

$1,000

Senior Secured Convertible Debentures, amount

15,000,000

Warrants issued, exercise price

2.45

Warrants issued to purchase common stock

11,000,000

Common stock, stated value per share

$0.00

[1]

$0.00

Closing date of offering

24-Jul-14

Preferred stock converted to common stock, value

4,800,000

Debentures converted to common stock

5,800,000

Common stock conversion price

$2.56

Warrants issued

4,800,000

6,200,000

Warrants, expiration period

'18 months

'5 years

Penalty payable for not meeting filing requirements

$3,300,000

Debentures annual interest rate

4.00%

Percentage of securities offered for investors

50.00%

[1]

Derived from the audited balance sheet as of December 31, 2013